[Modern Concepts of Genetic and Immunohistochemical Features of Prolactin-secreting Pituitary Adenomas]

Overview

Journal Probl Endokrinol (Mosk)

Specialty Endocrinology

Date 2023 Jul 14

PMID 37448246

Authors

A S Shutova

L K Dzeranova

S Yu Vorotnikova

M A Kutin

E A Pigarova

Affiliations

Soon will be listed here.

Abstract

Prolactinomas are the most common secreting adenomas of the pituitary. In 20% of cases resistance to dopamine-agonists treatment is observed. Medical therapy resistance causes progression of pathological symptoms of hyperprolactinemia and negative topographic and anatomical changes of prolactinoma. The causes of ineffectiveness of dopamine agonists therapy are not fully understood as well as approaches to managing patients require clarification. Current concepts of resistance are based on the data obtained as a result of surgery or after a period of long-term ineffective therapy. Thus, it is very important to find methods of assessing the sensitivity of prolactin-secreting adenomas to drug therapy before surgical treatment. Genetic and immunohistochemical studies find special place among these methods, making it possible to predict adenoma's response to drug therapy at early diagnostic stage. Obtained results will allow us to form personalized algorithm for managing patients.

References

Maiter D . Management of Dopamine Agonist-Resistant Prolactinoma. Neuroendocrinology. 2018; 109(1):42-50. DOI: 10.1159/000495775. View

Chen Y, Gao H, Xie W, Guo J, Fang Q, Zhao P . Genomic and transcriptomic analysis of pituitary adenomas reveals the impacts of copy number variations on gene expression and clinical prognosis among prolactin-secreting subtype. Aging (Albany NY). 2021; 13(1):1276-1293. PMC: 7834992. DOI: 10.18632/aging.202304. View

Di Sarno A, Landi M, Cappabianca P, Di Salle F, Rossi F, Pivonello R . Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001; 86(11):5256-61. DOI: 10.1210/jcem.86.11.8054. View

Valea A, Sandru F, Petca A, Dumitrascu M, Carsote M, Petca R . Aggressive prolactinoma (Review). Exp Ther Med. 2021; 23(1):74. PMC: 8652381. DOI: 10.3892/etm.2021.10997. View

Molitch M . Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017; 317(5):516-524. DOI: 10.1001/jama.2016.19699. View

Caimari F, Korbonits M . Novel Genetic Causes of Pituitary Adenomas. Clin Cancer Res. 2016; 22(20):5030-5042. DOI: 10.1158/1078-0432.CCR-16-0452. View

Fedorova N, Abrosimov A, Dzeranova L, Pigarova E, Dedov I . [Pituitary lactotroph adenomas resistant to dopamine agonist treatment: histological and immunohistochemical characteristics]. Arkh Patol. 2018; 80(3):34-39. DOI: 10.17116/patol201880334-39. View

Miao Y, Li C, Guo J, Wang H, Gong L, Xie W . Identification of a novel somatic mutation of POU6F2 by whole-genome sequencing in prolactinoma. Mol Genet Genomic Med. 2019; 7(12):e1022. PMC: 6900357. DOI: 10.1002/mgg3.1022. View

Agarwal S, Mateo C, Marx S . Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J Clin Endocrinol Metab. 2009; 94(5):1826-34. PMC: 2684477. DOI: 10.1210/jc.2008-2083. View

10.

Vasilev V, Daly A, Zacharieva S, Beckers A . Clinical and Molecular Update on Genetic Causes of Pituitary Adenomas. Horm Metab Res. 2020; 52(8):553-561. DOI: 10.1055/a-1143-5930. View

11.

Donoho D, Laws Jr E . The Role of Surgery in the Management of Prolactinomas. Neurosurg Clin N Am. 2019; 30(4):509-514. DOI: 10.1016/j.nec.2019.05.010. View

12.

Moncho-Amor V, Chakravarty P, Galichet C, Matheu A, Lovell-Badge R, Rizzoti K . SOX2 is required independently in both stem and differentiated cells for pituitary tumorigenesis in -null mice. Proc Natl Acad Sci U S A. 2021; 118(7). PMC: 7896314. DOI: 10.1073/pnas.2017115118. View

13.

Daly A, Beckers A . The Epidemiology of Pituitary Adenomas. Endocrinol Metab Clin North Am. 2020; 49(3):347-355. DOI: 10.1016/j.ecl.2020.04.002. View

14.

Li C, Xie W, Rosenblum J, Zhou J, Guo J, Miao Y . Somatic SF3B1 hotspot mutation in prolactinomas. Nat Commun. 2020; 11(1):2506. PMC: 7237453. DOI: 10.1038/s41467-020-16052-8. View

15.

Gao H, Wang F, Lan X, Li C, Feng J, Bai J . Lower PRDM2 expression is associated with dopamine-agonist resistance and tumor recurrence in prolactinomas. BMC Cancer. 2015; 15:272. PMC: 4407330. DOI: 10.1186/s12885-015-1267-0. View

16.

Wong A, Eloy J, Couldwell W, Liu J . Update on prolactinomas. Part 2: Treatment and management strategies. J Clin Neurosci. 2015; 22(10):1568-74. DOI: 10.1016/j.jocn.2015.03.059. View

17.

Caccavelli L, Morange-Ramos I, Kordon C, Jaquet P, Enjalbert A . Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol. 1996; 8(10):737-46. DOI: 10.1046/j.1365-2826.1996.04902.x. View

18.

Hodson D, Schaeffer M, Romano N, Fontanaud P, Lafont C, Birkenstock J . Existence of long-lasting experience-dependent plasticity in endocrine cell networks. Nat Commun. 2012; 3:605. PMC: 3272579. DOI: 10.1038/ncomms1612. View

19.

Fauquier T, Rizzoti K, Dattani M, Lovell-Badge R, Robinson I . SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland. Proc Natl Acad Sci U S A. 2008; 105(8):2907-12. PMC: 2268558. DOI: 10.1073/pnas.0707886105. View

20.

Lim C, Korbonits M . UPDATE ON THE CLINICOPATHOLOGY OF PITUITARY ADENOMAS. Endocr Pract. 2018; 24(5):473-488. DOI: 10.4158/EP-2018-0034. View